Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
:CRGX
CRGX Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CARGO Therapeutics, Inc. News
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is CARGO Therapeutics, Inc.’s market cap?
Currently, no data Available
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CARGO Therapeutics, Inc. have?
Currently, no data Available
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CRGX
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc. (CRGX) is a biotechnology company focused on developing advanced therapies in the field of oncology. The company specializes in creating innovative chimeric antigen receptor T-cell (CAR-T) therapies designed to target and eliminate cancer cells. Operating within the biotechnology and healthcare sectors, CARGO Therapeutics is committed to advancing cancer treatment through cutting-edge research and clinical trials aimed at providing patients with effective and personalized therapeutic options.
Ownership Overview
―
Insiders
11.55%
Mutual Funds
― Other Institutional Investors
88.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---